Literature DB >> 31790152

Coffee, green tea and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population.

Keitaro Tanaka1, Akiko Tamakoshi2, Yumi Sugawara3, Tetsuya Mizoue4, Manami Inoue5, Norie Sawada5, Keitaro Matsuo6, Hidemi Ito6, Mariko Naito7, Chisato Nagata8, Yuri Kitamura9, Atsuko Sadakane10, Shoichiro Tsugane5, Taichi Shimazu5.   

Abstract

BACKGROUND: Coffee and green tea, two popular drinks in the Japanese, have recently drawn much attention as potential protective factors against the occurrence of liver cancer.
METHODS: We systematically reviewed epidemiologic studies on coffee, green tea and liver cancer among Japanese populations. Original data were obtained by searching the MEDLINE (PubMed) and Ichushi databases, complemented with manual searches. The evaluation was performed in terms of the magnitude of association in each study and the strength of evidence ('convincing', 'probable', 'possible', or 'insufficient'), together with biological plausibility.
RESULTS: We identified four cohort and four case-control studies on coffee and liver cancer and six cohort and one case-control studies on green tea and liver cancer. All cohort and case-control studies on coffee reported a weak to strong inverse association, with a summary relative risk (RR) for one cup increase being 0.72 (95% confidence interval [CI] 0.66-0.79). Conversely, all studies but two cohort studies on green tea reported no association, with a corresponding summary RR of 0.99 (95% CI 0.97-1.01, P = 0.37).
CONCLUSION: Coffee drinking 'probably' decreases the risk of primary liver cancer among the Japanese population whereas the evidence on an association between green tea and liver cancer is 'insufficient' in this population.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Japanese; coffee; green tea; liver cancer; meta-analysis; systematic review

Year:  2019        PMID: 31790152     DOI: 10.1093/jjco/hyz097

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

Review 1.  Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence.

Authors:  Sarah Krull Abe; Manami Inoue
Journal:  Eur J Clin Nutr       Date:  2020-08-20       Impact factor: 4.016

2.  Associations between six dietary habits and risk of hepatocellular carcinoma: A Mendelian randomization study.

Authors:  Yunyang Deng; Junjie Huang; Martin C S Wong
Journal:  Hepatol Commun       Date:  2022-06-06

Review 3.  Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome.

Authors:  Adriana C Vidal; Cynthia A Moylan; Julius Wilder; Delores J Grant; Susan K Murphy; Cathrine Hoyo
Journal:  Front Oncol       Date:  2022-08-22       Impact factor: 5.738

4.  Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer.

Authors:  Yurie Seto; Yoshiko Kaneko; Takako Mouri; Daisuke Shimizu; Yoshie Morimoto; Shinsaku Tokuda; Masahiro Iwasaku; Tadaaki Yamada; Koichi Takayama
Journal:  Transl Lung Cancer Res       Date:  2022-09

Review 5.  Anti-Cancer Effects of Green Tea Epigallocatchin-3-Gallate and Coffee Chlorogenic Acid.

Authors:  Sumio Hayakawa; Tomokazu Ohishi; Noriyuki Miyoshi; Yumiko Oishi; Yoriyuki Nakamura; Mamoru Isemura
Journal:  Molecules       Date:  2020-10-05       Impact factor: 4.411

Review 6.  Advances in Nanodelivery of Green Tea Catechins to Enhance the Anticancer Activity.

Authors:  Yike Jiang; Ziyi Jiang; Lan Ma; Qingrong Huang
Journal:  Molecules       Date:  2021-05-31       Impact factor: 4.411

Review 7.  A Decade of Research on Coffee as an Anticarcinogenic Beverage.

Authors:  Ayelén D Nigra; Anderson J Teodoro; Germán A Gil
Journal:  Oxid Med Cell Longev       Date:  2021-09-15       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.